← Back to Search

Procedure

Enhanced Recovery After Surgery in Kidney Transplant Donors

N/A
Recruiting
Led By Uzong Yoon, MD, MPH
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from arrival to pacu until post-operative day 2 (48 hours)
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to study the effectiveness of an ERAS pathway for patients undergoing living donor nephrectomy. The hypothesis is that this will lead to faster recovery, early bowel function, decreased postoperative pain, increased patient satisfaction and shorter length of stay.

Eligible Conditions
  • Kidney Disease
  • Infections
  • Postoperative Complications
  • Postoperative Nausea and Vomiting
  • Opioid Use Disorder
  • Postoperative Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from arrival to pacu until post-operative day 2 (48 hours)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from arrival to pacu until post-operative day 2 (48 hours) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
post operative opioid consumption
Secondary study objectives
duration of hospitalization
patient satisfaction
time to first oral intake
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Enhanced recovery after surgeryExperimental Treatment5 Interventions
Preoperatively, patients will be counseled on optimization of physical and nutritional status. They will receive carbohydrate loading drinks prior to surgery. Intraoperatively, standard ASA monitors will be utilized, and patients will receive general anesthesia. Goal directed fluid management will be enforced with bolus options based on hemodynamics. Transabdominal plane and rectus sheath block will be performed in the operating room by the regional anesthesia team. Post-operatively pain management will include multimodal analgesic medications. Regular diet will be allowed and encouraged on post-operative day 0 (POD). Lines and drains will be minimized to encourage early mobilization and bowel function. Patients will be counseled on expectations of discharge criteria POD0.
Group II: Standard of careActive Control1 Intervention
Patients will receive traditional care for donor nephrectomy. Patients will be instructed to fast for 24 hours preoperative. On day of surgery, standard monitors will be used, and intraoperative management per anesthesiologists discretion including pain management. Post-operative, patients will receive pain medications, including opioids, as needed. Intravenous fluids will be continued until patients tolerate liquids per os. Bowel regimen will be ordered as needed. Patients will be discharged once meeting pre-set criteria.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
regional anesthesia
2009
Completed Phase 3
~64380

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
464 Previous Clinical Trials
175,707 Total Patients Enrolled
Uzong Yoon, MD, MPHPrincipal InvestigatorThomas Jefferson University
~7 spots leftby Dec 2025